Ionis Pharmaceuticals Inc (IONS)
41.59
-0.25
(-0.60%)
USD |
NASDAQ |
Apr 26, 16:00
41.58
-0.01
(-0.02%)
After-Hours: 20:00
Ionis Pharmaceuticals Research and Development Expense (Quarterly): 256.56M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 256.56M |
| September 30, 2023 | 215.33M |
| June 30, 2023 | 229.93M |
| March 31, 2023 | 197.81M |
| December 31, 2022 | 308.27M |
| September 30, 2022 | 182.99M |
| June 30, 2022 | 180.76M |
| March 31, 2022 | 161.13M |
| December 31, 2021 | 179.58M |
| September 30, 2021 | 184.77M |
| June 30, 2021 | 139.31M |
| March 31, 2021 | 139.80M |
| December 31, 2020 | 170.78M |
| September 30, 2020 | 125.08M |
| June 30, 2020 | 122.26M |
| March 31, 2020 | 116.95M |
| December 31, 2019 | 148.74M |
| September 30, 2019 | 104.37M |
| June 30, 2019 | 106.16M |
| March 31, 2019 | 106.42M |
| December 31, 2018 | 113.45M |
| September 30, 2018 | 95.26M |
| June 30, 2018 | 101.83M |
| March 31, 2018 | 104.07M |
| December 31, 2017 | 128.29M |
| Date | Value |
|---|---|
| September 30, 2017 | 80.21M |
| June 30, 2017 | 83.51M |
| March 31, 2017 | 82.64M |
| December 31, 2016 | 101.15M |
| September 30, 2016 | 84.63M |
| June 30, 2016 | 77.57M |
| March 31, 2016 | 80.96M |
| December 31, 2015 | 101.33M |
| September 30, 2015 | 88.51M |
| June 30, 2015 | 68.01M |
| March 31, 2015 | 64.45M |
| December 31, 2014 | 67.95M |
| September 30, 2014 | 61.09M |
| June 30, 2014 | 59.26M |
| March 31, 2014 | 53.45M |
| December 31, 2013 | 57.43M |
| September 30, 2013 | 45.66M |
| June 30, 2013 | 42.63M |
| March 31, 2013 | 38.31M |
| December 31, 2012 | 42.76M |
| September 30, 2012 | 36.55M |
| June 30, 2012 | 40.44M |
| March 31, 2012 | 38.71M |
| December 31, 2011 | 47.22M |
| September 30, 2011 | 39.92M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
104.37M
Minimum
Sep 2019
308.27M
Maximum
Dec 2022
172.14M
Average
170.78M
Median
Dec 2020
Research and Development Expense (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | 70.64M |
| Viking Therapeutics Inc | 24.10M |
| Alnylam Pharmaceuticals Inc | 272.14M |
| Akero Therapeutics Inc | 53.39M |
| 89bio Inc | 33.59M |